Abstract 114P
Background
Pathogenic or likely pathogenic germline variants (PGVs) in cancer predisposition genes may play a role in lung cancer (LC) susceptibility. However, determining an eligible population for genetic testing remains uncertain. This study aimed to assess the prevalence of PGVs in a selected cohort of individuals with lung adenocarcinoma.
Methods
A cross-sectional cohort study was conducted to assess PGVs rate in lung adenocarcinoma patients with a family history of LC, young-onset presentation, history of never/light smoking, or actionable genomic alterations (AGAs). Sequencing was performed using Sophia Hereditary Cancer Solution panel F, including 144 cancer predisposition genes. Variants classified as pathogenic or likely pathogenic were included for further analysis.
Results
We incluided 201 patients, of which 43 (21.4%) exhibited PGVs, identifying that 64.5% occurred in DNA damage repair genes, being 86.1% clinically actionable. The most frequent PGVs were found in ATM (9.3%), TP53 (6.9%), BRCA2 (6.9%), and CHEK2 (6.9%) genes. PGVs were associated with male sex (adjusted odds ratio [aOR] 2.54, 95% CI 1.17–5.53, p=0.019), very young-onset presentation (aOR 5.79, 95% CI 1.35–24.74, p=0.018), and first-degree relatives with LC (aOR 3.78, 95% CI 1.11–12.83, p=0.033), along with a trend toward association with AGAs (aOR 6.42, 95% CI 0.79–52.18, p=0.082).
Conclusions
This study identified a high PGVs prevalence based on our selection criteria, thus representing an effective strategy to select candidates for germline genomic testing, potential screening strategies in close relatives, and personalized therapeutic modalities. Our results warrant further exploration in other populations to confirm them.
Clinical trial identification
NCT06181812.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was supported by CONAHCyT (A3-S-47960) and Becas Impulso a La Investigación En Salud “Carlos Slim” 2023 (N20230149).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - 23ME-01473, an Fc-enhanced anti-ULBP6/2/5 antibody, restores anti-tumor NK cell function through NKG2D and FcgRIIIa activation
Presenter: Kim Gerrick
Session: Poster session 08
154P - Phase II study of nivolumab and relatlimab utilizing single cell analysis of circulating T cells reveals immune features associated with response to dual PD-1 and LAG-3 inhibition
Presenter: James Dollar
Session: Poster session 08
155P - The molecular basis of the lymphocyte stability index (LSI): A pan-cancer peripheral biomarker for survival post immune checkpoint blockade (ICB)
Presenter: Robert Watson
Session: Poster session 08
156P - Microbiota-related multiomics to assess the clinical relevance of antibiotics (ATB) in immunotherapy (ICI)
Presenter: Adele Bonato
Session: Poster session 08
157P - Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy
Presenter: Joao Gorgulho
Session: Poster session 08
158P - Patterns of immune-related adverse events in early-phase cancer immunotherapy trials
Presenter: Benjamin Fairfax
Session: Poster session 08
160P - Predicting immune-related adverse events using biomarkers in early-phase cancer immunotherapy trials
Presenter: Benjamin Fairfax
Session: Poster session 08
161P - Fibroblast activation protein (FAP)-CD40 (RO7300490) mediates intratumoral DC maturation and modulation of the tumor microenvironment
Presenter: Ignacio Melero
Session: Poster session 08
162P - Exploiting gp100-specific antibodies isolated from immune checkpoint inhibitor-responsive melanoma patients to target tumor cells
Presenter: Lukas Flatz
Session: Poster session 08